Literature DB >> 20518081

Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease.

Marla Cindy Dubinsky1.   

Abstract

The search for biologic markers that can assess the natural history and perhaps predict the course of individual's disease including response to treatments over time has become an important focus of inflammatory bowel disease research. The knowledge of an individual's prognosis can help physicians and patients make important management decisions and aid communication on risk and benefits of disease and treatment.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20518081      PMCID： PMC2880772          DOI： 10.3748/wjg.v16.i21.2604

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  48 in total

1.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

2.  Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease.

Authors:  S K Bunn; W M Bisset; M J Main; B E Golden
Journal:  J Pediatr Gastroenterol Nutr       Date:  2001-02       Impact factor: 2.839

3.  Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.

Authors:  Javier P Gisbert; Fernando Bermejo; Jose-Lázaro Pérez-Calle; Carlos Taxonera; Isabel Vera; Adrian G McNicholl; Alicia Algaba; Pilar López; Natalia López-Palacios; Marta Calvo; Yago González-Lama; Jose-Antonio Carneros; Marta Velasco; José Maté
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

4.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

5.  Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease.

Authors:  O Cohavy; G Harth; M Horwitz; M Eggena; C Landers; C Sutton; S R Targan; J Braun
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

6.  Colonic bacteria express an ulcerative colitis pANCA-related protein epitope.

Authors:  O Cohavy; D Bruckner; L K Gordon; R Misra; B Wei; M E Eggena; S R Targan; J Braun
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

7.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

Authors:  J A Tibble; G Sigthorsson; S Bridger; M K Fagerhol; I Bjarnason
Journal:  Gastroenterology       Date:  2000-07       Impact factor: 22.682

8.  Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene.

Authors:  A J Szalai; M A McCrory; G S Cooper; J Wu; R P Kimberly
Journal:  Genes Immun       Date:  2002-02       Impact factor: 2.676

9.  High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis.

Authors:  P R Fleshner; E A Vasiliauskas; L Y Kam; N E Fleshner; J Gaiennie; M T Abreu-Martin; S R Targan
Journal:  Gut       Date:  2001-11       Impact factor: 23.059

10.  Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens.

Authors:  Carol J Landers; Offer Cohavy; Rajeev Misra; Huiying Yang; Ying-Chao Lin; Jonathan Braun; Stephan R Targan
Journal:  Gastroenterology       Date:  2002-09       Impact factor: 22.682
View more
  13 in total

1.  Prediction of disease course in inflammatory bowel diseases.

Authors:  Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 2.  The Role of Early Biologic Therapy in Inflammatory Bowel Disease.

Authors:  Dana Rachel Berg; Jean-Frederic Colombel; Ryan Ungaro
Journal:  Inflamm Bowel Dis       Date:  2019-11-14       Impact factor: 5.325

3.  In the pipeline.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-06

4.  Risk assessment in Crohn's disease.

Authors:  Marla C Dubinsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-06

5.  Inflammatory bowel disease unclassified.

Authors:  Ning Zhou; Wei-xing Chen; Shao-hua Chen; Cheng-fu Xu; You-ming Li
Journal:  J Zhejiang Univ Sci B       Date:  2011-04       Impact factor: 3.066

6.  Crohn's disease: the first visit.

Authors:  Jack A Di Palma; Francis A Farraye
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-03

7.  Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis.

Authors:  Siddharth P Sura; Awais Ahmed; Adam S Cheifetz; Alan C Moss
Journal:  J Clin Gastroenterol       Date:  2014-04       Impact factor: 3.062

Review 8.  Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.

Authors:  Bram Verstockt; Nurulamin M Noor; Urko M Marigorta; Polychronis Pavlidis; Parakkal Deepak; Ryan C Ungaro
Journal:  J Crohns Colitis       Date:  2021-09-25       Impact factor: 9.071

9.  Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul.

Authors:  Hiroshi Nakase; Bora Keum; Byoung Duk Ye; Soo Jung Park; Hoon Sup Koo; Chang Soo Eun
Journal:  Intest Res       Date:  2016-06-27

10.  Results of the first survey for the current status of inflammatory bowel disease management in Asian countries.

Authors:  Ji Won Kim
Journal:  Intest Res       Date:  2016-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.